Matija Peterlin, MD


  1. Proteasomal Inhibition Potentiates Latent HIV Reactivation.
  2. HIV Transcription is Independent of Mediator Kinases.
  3. Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1.
  4. HEXIM1-Tat chimera inhibits HIV-1 replication.
  5. Bromodomain-containing protein 4-independent transcriptional activation by autoimmune regulator (AIRE) and NF-?B.
  6. Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA.
  7. Natural Products and HIV/AIDS.
  8. Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors.
  9. Nef is secreted in exosomes from Nef.GFP-expressing and HIV-1-infected human astrocytes.
  10. Hili Inhibits HIV Replication in Activated T Cells.
  11. Euphorbia Kansui Reactivates Latent HIV.
  12. FBXO3 Protein Promotes Ubiquitylation and Transcriptional Activity of AIRE (Autoimmune Regulator).
  13. Targeting the latent reservoir to achieve functional HIV cure.
  14. CDK11 in TREX/THOC Regulates HIV mRNA 3' End Processing.
  15. Cyclin-dependent kinase 12 increases 3' end processing of growth factor-induced c-FOS transcripts.
  16. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.
  17. Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription.
  18. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.
  19. Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G.
  20. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein.
  21. PKC phosphorylates HEXIM1 and regulates P-TEFb activity.
  22. Moloney leukemia virus type 10 inhibits reverse transcription and retrotransposition of intracisternal a particles.
  23. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
  24. 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription.
  25. P bodies inhibit retrotransposition of endogenous intracisternal a particles.
  26. Transcription elongation takes central stage: the P-TEFb connection.
  27. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells.
  28. Repression of RNA polymerase II elongation in vivo is critically dependent on the C-terminus of Spt5.
  29. Genetic analysis of P-TEFb function via heterologous nucleic acid tethering systems.
  30. 7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development.
  31. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
  32. Transcriptional interference antagonizes proviral gene expression to promote HIV latency.
  33. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire.
  34. Tat-SIRT1 tango.
  35. APOBEC3 proteins and reverse transcription.
  36. Vpr.A3A chimera inhibits HIV replication.
  37. Differential chromatin looping regulates CD4 expression in immature thymocytes.
  38. AIRE recruits P-TEFb for transcriptional elongation of target genes in medullary thymic epithelial cells.
  39. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription.
  40. Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histocompatibility complex class II transcription in macrophages.
  41. Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters.
  42. Controlling the elongation phase of transcription with P-TEFb.
  43. Distal regulation of alternative splicing by splicing enhancer in equine beta-casein intron 1.
  44. HIV latency: present knowledge, future directions.
  45. Oligomerization of HEXIM1 via 7SK snRNA and coiled-coil region directs the inhibition of P-TEFb.
  46. Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb.
  47. Runx1 binds positive transcription elongation factor b and represses transcriptional elongation by RNA polymerase II: possible mechanism of CD4 silencing.
  48. Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation.
  49. Intracellular immunity to HIV-1: newly defined retroviral battles inside infected cells.
  50. A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation.
  51. Newly identified host factors modulate HIV replication.
  52. Expression of MHC II genes.
  53. Transcriptional activity and substrate recognition of cyclin T2 from P-TEFb.
  54. VP16 and ubiquitin; binding of P-TEFb via its activation domain and ubiquitin facilitates elongation of transcription of target genes.
  55. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
  56. Nef binds p6* in GagPol during replication of human immunodeficiency virus type 1.
  57. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element.
  58. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis.
  59. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir.
  60. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.
  61. Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells.
  62. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions.
  63. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?
  64. A model of repression: CTD analogs and PIE-1 inhibit transcriptional elongation by P-TEFb.
  65. Hide, shield and strike back: how HIV-infected cells avoid immune eradication.
  66. A minimal chimera of human cyclin T1 and tat binds TAR and activates human immunodeficiency virus transcription in murine cells.
  67. Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression.
  68. Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters.
  69. Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome.
  70. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.
  71. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy.
  72. Subunit H of the V-ATPase involved in endocytosis shows homology to beta-adaptins.
  73. Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery.
  74. Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV.
  75. P-TEFb containing cyclin K and Cdk9 can activate transcription via RNA.
  76. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA.
  77. Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes.
  78. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.
  79. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II.
  80. Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes.
  81. Nef from human immunodeficiency virus type 1(F12) inhibits viral production and infectivity.
  82. Structure--function relationships in HIV-1 Nef.
  83. Nef increases infectivity of HIV via lipid rafts.
  84. Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef.
  85. Lessons from HIV: movement of macromolecules inside the cell.
  86. Negative factor from SIV binds to the catalytic subunit of the V-ATPase to internalize CD4 and to increase viral infectivity.
  87. Endocytic entry of HIV-1.
  88. Binding of Tat to TAR and recruitment of positive transcription elongation factor b occur independently in bovine immunodeficiency virus.
  89. Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex.
  90. Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1.
  91. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection.
  92. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation.
  93. The class II transactivator CIITA is a transcriptional integrator.
  94. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions.
  95. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b.
  96. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T.
  97. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes.
  98. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat.
  99. Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4.
  100. Activation of the T-cell receptor signaling pathway by Nef from an aggressive strain of simian immunodeficiency virus.
  101. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.
  102. Assembly of functional regulatory complexes on MHC class II promoters in vivo.
  103. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32.
  104. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme.
  105. Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys.
  106. CDC42 and Rac1 are implicated in the activation of the Nef-associated kinase and replication of HIV-1.
  107. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II.
  108. Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions.
  109. Binding and cooperative interactions between two B cell-specific transcriptional coactivators.
  110. A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity.
  111. Ets-1 activates the DRA promoter in B cells.
  112. Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1.
  113. NMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 Tat.
  114. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts.
  115. Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes.
  116. Effects of CD45 on NF-kappa B. Implications for replication of HIV-1.
  117. Synergism between Tat and VP16 in trans-activation of HIV-1 LTR.
  118. Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells.
  119. Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs.
  120. Juxtaposition between activation and basic domains of human immunodeficiency virus type 1 Tat is required for optimal interactions between Tat and TAR.
  121. Mapping cis-acting defects in promoters of transcriptionally silent DQA2, DQB2, and DOB genes.
  122. The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat.
  123. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.
  124. B-cell factor 1 is required for optimal expression of the DRA promoter in B cells.
  125. Transcriptional regulation of HLA-DRA gene.
  126. Human immunodeficiency virus type 1 Tat does not transactivate mature trans-acting responsive region RNA species in the nucleus or cytoplasm of primate cells.
  127. Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals.
  128. NF-X2 that binds to the DRA X2-box is activator protein 1. Expression cloning of c-Jun.
  129. Trans-activation by HIV-1 Tat via a heterologous RNA binding protein.
  130. Mutational analysis of the DRA promoter: cis-acting sequences and trans-acting factors.
  131. Transcriptional regulation of HLA class-II genes.
  132. trans-activation by the hepatitis B virus X protein shows cell-type specificity.
  133. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.
  134. Evidence for a trans-acting factor that regulates the transcription of class II major histocompatibility complex genes: genetic and functional analysis.
  135. B-cell-specific and interferon-gamma-inducible regulation of the HLA-DR alpha gene.
  136. Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein.
  137. Transcription and replication of human immunodeficiency virus-1 in B lymphocytes in vitro.
  138. Characterization of the human monocyte high affinity Fc receptor (hu FcRI).
  139. Molecular biology of HIV.
  140. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.
  141. Monoclonal antibody immunoprecipitation of cell membrane glycoproteins.
  142. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals.
  143. Mutant human B cell lines deficient in class II major histocompatibility complex transcription.
  144. Transcriptional enhancers in the HLA-DQ subregion.
  145. A model for the transcriptional regulation of MHC class II genes.